WT1 and myeloid leukemia: Furthermore, administration of 17-AAG, a clinically available inhibitor of WT1 (via its interaction with heat shock protein 90), was shown to decrease myeloid leukemia xenograft growth, correlating with decreased expression of WT1 and its downstream targets50.